Dina Titus Stock Trades

The financial disclosure record for Representative Dina Titus of Nevada's 1st District contains 21 transactions dated between 2014 and early 2017, with no later transactions in the database. That alone sets her apart from a large share of her colleagues: 276 of the 537 members currently sitting in Congress have no disclosed trades on file at all. But the shape of Titus's record is just as telling as its existence. Only 13 of the 21 transactions are attributed to her personally. Six are tied to a spouse, one is joint, and one carries no attribution code at all. The activity is also heavily weighted toward fixed-income and other non-equity instruments rather than named individual stocks, a pattern visible throughout the disclosed security names.

Trading Activity and Attribution Over Time

The record runs from a sale on February 9, 2014 to a purchase on January 3, 2017, disclosed in a filing dated January 13, 2017. That final transaction, a purchase of a Massachusetts state general municipal bond in the $15,001 to $50,000 range, was attributed to her spouse. Activity across the four years covered was uneven. 2014 produced five transactions, four of them purchases. 2015 was balanced, with three purchases and three sales among six total transactions. 2016 was the busiest and most sale-heavy year by far, with nine transactions split three purchases to six sales. 2017 contributed a single purchase before the disclosed record ends.

Of the 21 transactions, 11 are purchases and 10 are sales, evenly split overall despite the lopsided 2016 total. On attribution, 13 transactions are marked "Self," six are marked "Spouse," one is marked "Joint," and one carries an "Unknown" code, meaning the source data does not identify the transaction's attribution. Under House disclosure rules, filings of this kind can reflect the member's own transactions or those attributed to a spouse, dependent child, or joint ownership, and the attribution codes in this record should be read accordingly rather than assumed to represent the member's personal trading in every case. House Ethics guidance on the disclosure process explains this attribution structure in more detail.

Instrument Mix and Most Frequently Disclosed Securities

Sector activity in the record is dominated by an "Unknown" classification, covering 18 of the 21 transactions. Those entries include a broad mix of instruments: municipal bonds (a Massachusetts general municipal bond, an Illinois financing authority health revenue bond, a Nevada higher education bond, a Las Vegas general refunding issue, and a Washington State issue), preferred stock (two separate Public Storage preferred stock sales and a BB&T Corporation preferred stock purchase), corporate debt (an E*Trade Financial Corp bond purchase), a Franklin U.S. Government Securities sale, and a Nationwide Annuity purchase. Only two named sectors appear in the record: Health Care, with two transactions, and Financials, with one.

The most frequently disclosed ticker by transaction-row count is BKP, which appears twice, both as purchases attributed to her spouse and both dated November 28, 2014. One entry is named “Boston Properties (BKP),” while the other is listed as “Vaknapo (BKP).” That filing also discloses a same-day purchase in Washington State debt and, on November 4, 2014, a purchase of Capital One Financial Corporation (COF) carrying an "Unknown" attribution code. Capital One is the holding company for Capital One, National Association, operating Credit Card, Consumer Banking, and Commercial Banking segments across the United States, Canada, and the United Kingdom.

The two Health Care names in the record were both sales attributed to Titus personally. On November 24, 2015, the disclosure shows a sale of Bristol-Myers Squibb (BMY), a biopharmaceutical company whose products span oncology treatments including Opdivo and Breyanzi, immunology drugs such as Orencia, and Eliquis. That filing also discloses a Nationwide Annuity purchase five days later and a Franklin U.S. Government Securities sale the day after the Bristol-Myers Squibb transaction. On November 21, 2016, the record shows a sale of AstraZeneca (AZN), a UK-headquartered biopharmaceutical company with products spanning oncology, cardiovascular and renal disease, and respiratory and immunology treatments, including Tagrisso, Farxiga, and Symbicort. That transaction was disclosed in a December 2, 2016 filing.

The record does not currently carry a Quantellect score for Titus. No score row exists for her at the latest published score date of August 21, 2026, when 76 members had a published score, including 73 sitting members.

About This Data

This profile is built from periodic transaction reports that members of Congress are required to file under the Stop Trading on Congressional Knowledge Act of 2012. STOCK Act Amounts are disclosed in statutory ranges rather than exact dollar figures, and transaction dates can precede the public filing date by weeks or months, as several entries above illustrate. Transactions may be attributed to the member, a spouse, a dependent child, or joint ownership, and attribution is based on the code provided in the underlying filing. This page reflects the disclosure record as currently available in our database and is not investment advice.